A Patient’s Guide to Clinical Trials
En Español | En Français
NIH Clinical Research Trials and You
Guidance regarding HIV anti-retroviral treatment in developing countries
Policy on Research Involving Human Subjects
Current therapy of eosinophilic esophagitis and eosinophilic gastroenteritis is limited to highly restrictive elimination diets or off-label use of corticosteroids. This investigational study will examine the safety and effectiveness of low-dose sirolimus in reducing high blood and tissue eosinophil counts in patients with eosinophil-associated gastrointestinal disorders. Sirolimus is Food and Drug Administration (FDA)-approved for use in kidney transplant recipients to prevent organ rejection.
You may be eligible if you
Participants will take sirolimus daily for two months and will travel to the National Institutes of Health (NIH) five times over five months for check-ups and blood draws; some participants may require one to two additional visits over one to two months. Participants will have an upper GI endoscopy at the beginning and end of the study.
The study is being conducted at the Warren Grant Magnuson Clinical Center at NIH in Bethesda, Maryland. The NIH campus is accessible by car and public transportation.
There is no charge to participate in this research study. All study-related medical care and procedures are provided free of charge.
There is no compensation for study participation. Transportation and other expenses may be covered.
To see if you may qualify or for more information contact
Patient Recruitment and Public Liaison Office, NIH Clinical CenterToll Free: 1-800-411-1222 (reference study# 13-I-0094)TTY: 1-866-411-1010 Se habla español.Email: firstname.lastname@example.org Office hours: 8:00 a.m.-3:30 p.m. Eastern Time
To learn more about this study of sirolimus in treating eosinophil-associated gastrointestinal disorders (trial ID: NCT01814059), visit ClinicalTrials.gov.
Last Updated May 29, 2013
Last Reviewed February 13, 2015